کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5828489 | 1558963 | 2013 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Olanzapine induces glucose intolerance through the activation of AMPK in the mouse hypothalamus
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
AMPKi.p.intracerebroventriculari.c.v.adenosine 5′-monophosphate-activated protein kinase - آدنوزین 5'-monophosphate-فعال پروتئین کینازanalysis of variance - تحلیل واریانسANOVA - تحلیل واریانس Analysis of varianceglucose tolerance test - تست تحمل گلوکزintraperitoneal - داخل صفاقیatypical antipsychotic drug - داروهای ضد روان پریشی غیرمعمول
موضوعات مرتبط
علوم زیستی و بیوفناوری
علم عصب شناسی
علوم اعصاب سلولی و مولکولی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Treatment with atypical antipsychotic drugs is known to increase the risk of glucose intolerance and diabetes. However, the mechanism of this effect is unclear. Since central adenosine 5â²-monophosphate-activated protein kinase (AMPK) plays an important role in regulating nutrient homeostasis, the present study was performed to examine the involvement of central AMPK in the glucose intolerance induced by olanzapine, an atypical antipsychotic drug, in mice. Acute intraperitoneal treatment with olanzapine dose-dependently increased blood glucose levels in the glucose tolerance test. Intracerebroventricular administration of olanzapine also increased blood glucose levels in the glucose tolerance test. The glucose intolerance induced by both intraperitoneal and intracerebroventricular treatment with olanzapine was significantly attenuated by intracerebroventricular pretreatment with the AMPK inhibitor compound C. Intracerebroventricular treatment with the AMPK activator AICAR increased blood glucose levels in the glucose tolerance test, and this increase was inhibited by compound C. Moreover, the hypothalamic level of phosphorylated AMPK after glucose injection was significantly increased by intracerebroventricular pretreatment with olanzapine. Olanzapine did not affect plasma glucagon and insulin levels. Our results indicate that acute treatment with olanzapine causes glucose intolerance through the activation of hypothalamic AMPK. The present study suggests that the inhibition of central AMPK activity may have a therapeutic effect on the metabolic disturbance induced by atypical antipsychotic drugs.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Journal of Pharmacology - Volume 718, Issues 1â3, 15 October 2013, Pages 376-382
Journal: European Journal of Pharmacology - Volume 718, Issues 1â3, 15 October 2013, Pages 376-382
نویسندگان
Megumi Ikegami, Hiroko Ikeda, Yoko Ishikawa, Masahiro Ohsawa, Takahiro Ohashi, Misa Kai, Atsuko Kamei, Junzo Kamei,